Neoprobe has received a nearly $250,000 grant from the qualifying therapeutic discovery project program, which was developed under the health reform law. "This cash award will provide additional support for the development of Lymphoseek, our lead program, without diluting the value of either our assets or our equity," President and CEO David C. Bupp said.

Full Story:

Related Summaries